Glenmark Pharmaceuticals gains as its arm launches Axitinib Tablets
Glenmark Pharmaceuticals is currently trading at Rs. 2663.00, up by 20.00 points or 0.76% from its previous closing of Rs. 2643.00 on the BSE.
The scrip opened at Rs. 2640.50 and has touched a high and low of Rs. 2685.00 and Rs. 2635.00 respectively. So far 5167 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2713.75 on 09-Nov-2026 and a 52 week low of Rs. 1811.00 on 17-Nov-2025.
Last one week high and low of the scrip stood at Rs. 2713.75 and Rs. 2571.20 respectively. The current market cap of the company is Rs. 75777.32 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.19% and 14.17% respectively.
Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Pharmaceuticals Inc., USA, (Glenmark) has launched Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA (axitinib) tablets. According to IQVIA sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA Tablets were around $538.4 million.
